Compugen Ltd (CGEN) Stock Analysis
Verdict: WATCH (do not buy)
Milestone cash creates a $90.6M balance sheet shield, but lumpy licensing revenue and Phase 1/2 clinical binary risks cap visibility.
Investment score: 57/100
Analysis as of
Is Compugen Ltd stock worth reviewing? The TradeMates thesis
Compugen combines a sturdy $90.6M cash reserve with high clinical-stage execution risk, warranting a HOLD until pipeline readouts confirm commercial viability.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Compugen Ltd opportunities and risks
What speaks for CGEN
- Robust Cash Runway
What speaks against CGEN
- Clinical Trial Binary Failure Risk
Frequently asked questions about Compugen Ltd (CGEN)
Is CGEN stock a good investment?
The TradeMates model rates Compugen Ltd as WATCH (do not buy) with an investment score of 57/100. Compugen combines a sturdy $90.6M cash reserve with high clinical-stage execution risk, warranting a HOLD until pipeline readouts confirm commercial viability. This is algorithmic model output, not personal investment advice.
Is CGEN stock a buy?
The TradeMates model verdict for CGEN is WATCH (do not buy) with an investment score of 57/100. Treat this as a model signal to review, not a personal buy recommendation.